NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
Intensity Therapeutics, Inc.
Nektar Therapeutics
St. Joseph Hospital of Orange
NSABP Foundation Inc
University of California, San Francisco
Northwell Health
Onkovis GmbH
H. Lee Moffitt Cancer Center and Research Institute
Xoft, Inc.
Stanford University
Onkovis GmbH
University College, London
Azaya Therapeutics, Inc.
Cytori Therapeutics
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
European Institute of Oncology